Morse Asset Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Morse Asset Management’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,400	Closed	-$609K	–	142
2018 Q2	$609K	Buy	13,400 +1,650	+14%	+$80.2K	0.17%	101
2018 Q1	$620K	Buy	11,750 +7,100	+153%	+$414K	0.17%	101
2017 Q4	$316K	Sell	4,650 -24,270	-84%	-$1.7M	0.09%	115
2017 Q3	$2.38M	Buy	+28,920	New	+$2.29M	0.71%	49

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morse Asset Management's CLVS Position: Q3 2018 in Review

Morse Asset Management sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 13,400 shares — an estimated $609K sold.

Morse Asset Management first reported a position in CLVS in Q3 2017 and held it in 4 quarters. The position peaked at $2.38M in Q3 2017. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

Morse Asset Management reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
Morse Asset Management sold 13,400 Clovis Oncology, Inc. shares in Q3 2018, an estimated $609K.
Morse Asset Management first reported a position in Clovis Oncology, Inc. in Q3 2017 and held it in 4 quarters.
Morse Asset Management's Clovis Oncology, Inc. position peaked at $2.38M in Q3 2017.
192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Morse Asset Management's 13F filing for Q3 2018, filed 1 Nov 2018.